Business Context and Reporting Period
This Form 8-K Current Report, dated August 12, 2022, details a material definitive agreement entered into by Palisade Bio, Inc. (PALI) with Ladenburg Thalmann & Co. Inc. The report covers the pricing and subsequent closing of a registered public offering of equity securities.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $12.2 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Securities Issued:
- 49,360,000 shares of Common Stock (including 7,200,000 from the full exercise of the overallotment option).
- 1,460 shares of Series B Preferred Stock.
- 55,200,000 Series 1 Warrants (1-year term, $0.25 exercise price).
- 55,200,000 Series 2 Warrants (5-year term, $0.25 exercise price).
- Offering Structure:
- Class A Units: 42,160,000 units sold at $0.25 per unit (1 Common Stock + 1 Series 1 Warrant + 1 Series 2 Warrant).
- Class B Units: 1,460 units sold at $1,000 per unit (1 Series B Preferred Stock + Warrants).
- Post-Offering Capitalization: As of August 16, 2022, 71,240,169 shares of Common Stock were outstanding (excluding shares issuable upon conversion of Series B Preferred Stock).
Material Changes
The primary material change is the significant increase in outstanding equity and the dilution resulting from the public offering. The Company fully exercised the 45-day overallotment option on August 12, 2022, increasing the total shares sold by 7,200,000. Additionally, the Company filed a Certificate of Designation for Series B Preferred Stock, which ranks on par with Common Stock regarding dividends and liquidation but generally lacks voting rights, subject to specific protective provisions.
Outlook, Risks, and Contingencies
- Lock-Up Agreements: The Company and its executive officers and directors are subject to a 90-day lock-up period following the Underwriting Agreement date, restricting the sale or transfer of securities without Underwriter approval.
- Warrant Call Provisions: The Company may call for the cancellation of Warrants if the volume-weighted average price of Common Stock exceeds 300% of the $0.25 exercise price for 30 consecutive trading days, provided average daily trading volume exceeds $500,000 and other conditions are met.
- Preferred Stock Conversion Limits: Conversion of Series B Preferred Stock is limited to prevent any holder from beneficially owning more than 4.99% (or up to 9.99% with notice) of outstanding Common Stock.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for a reporting period; it focuses solely on the capital raise transaction.
Investor Verification Checklist
- Verify the final net proceeds of $12.2 million against the actual cash received in the Company's subsequent 10-Q or 10-K filings.
- Confirm the exact date stockholder approval was obtained for warrant exercisability under Nasdaq rules.
- Monitor the 90-day lock-up expiration date to assess potential selling pressure from insiders.
- Review the Certificate of Designation (Exhibit 3.1) for specific details on the Series B Preferred Stock conversion mechanics and beneficial ownership limitations.
- Track the trading volume and price of Common Stock to determine if the "call" conditions for the Warrants are met.